Heplisav Postmarketing Worries Push PDUFA Date Back; FDA Seeks More Details

Dynavax's final pivotal trial for hepatitis B candidate was missing data from 150 patients, making its causality of myocardial infarctions unclear; the question now is whether the postmarketing trial can answer the question.

Hepatitis B

The wait for Dynavax Technologies Corp.'s hepatitis B vaccine candidate Heplisav (rHBsAg-1018 ISS) will continue on, as US FDA is delaying the product's Prescription Drug User Fee Act (PDUFA) date for with a request for more information to ensure the company has robust plans for a postmarketing study.

Dynavax CEO Eddie Gray said in a conference call Aug. 3 that FDA is specifically seeking to finalize details with...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers